Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02856893
Other study ID # EORTC-1613
Secondary ID ESR-15-11406
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date October 10, 2017
Est. completion date December 2027

Study information

Verified date September 2022
Source European Organisation for Research and Treatment of Cancer - EORTC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The phase II APPLE trial gives the opportunity to prospectively validate liquid biopsies as a new standard for testing tumor progression compared with conventional radiological procedure in EGFR mutant advanced NSCLC patients. Moreover based on the sequential T790M test during treatment the investigators will assess the predictive value of liquid biopsies. APPLE trial will examine the best strategy for delivering osimertinib (upfront versus sequential treatment after 1st generation EGFR TKI) in EGFR mutant NSCLC patients. Finally, the trial will also explore the mechanisms of acquired resistance to Osimertinib based on the results of an optional biopsy upon progression.


Description:

Primary objective To evaluate the best strategy for delivering Osimertinib (AZD9291) in NSCLC patients with EGFR mutation. The objective is assessed by Progression Free Survival rate at 18 months (PFS-18). Secondary objectives - To evaluate PFS on Osimertinib measured from randomization by RECIST criteria 1.1 [Ref 33]. - To evaluate PFS measured from switching to Osimertinib by RECIST criteria 1.1 [Ref 33]. - To determine the proportion of patients receiving Osimertinib based on the determination of cfDNA T790M mutation positive. - To evaluate time to symptomatic brain metastases in patients with presence of brain metastases at study entry. - To evaluate PFS-2 (defined as the sum of the PFS to Gefitinib and the PFS to Osimertinib treatment). - To evaluate Overall Response Rate (ORR) to Osimertinib. - To evaluate the Treatment duration. - To evaluate Time to progression (TTP) on Osimertinib (measured from switching to osimertinib). - To evaluate Overall Survival (OS). - To evaluate time to brain progression (TTBP). - Safety.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 156
Est. completion date December 2027
Est. primary completion date February 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion: Registration: - Pathological diagnosis of adenocarcinoma of the lung carrying common EGFR activating mutations associated with EGFR-TKI sensitivity (Del19 or L858R); performed locally; no other EGFR mutations will be allowed. In case of other (than EGFR) concomitant mutations, discussion with EORTC Headquarters is mandatory; - Stage IV NSCLC; - Blood sample available for cfDNA EGFR T790M central testing; - Age =18 years; - EGFR TKI treatment-naïve eligible to receive first-line treatment with EGFR TKI; - Prior adjuvant and neo-adjuvant therapy is permitted (chemotherapy, radiotherapy, investigational agents) if performed more than 12 months before registration; - Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations Randomization: - Report of adequacy sample for cfDNA EGFR T790M test by central laboratory; - Prior palliative radiotherapy or surgery are allowed if completed at least 4 weeks before the randomization; - Patients with brain metastases are allowed provided they are stable (i.e. without evidence of progression by imaging for at least two weeks prior to the first dose of trial treatment and without deterioration of any neurologic symptoms), and have not received steroids for at least 7 days before randomization; Baseline tumor assessment scans are done within 21 days before randomization; - Evaluable disease as defined below; - At least one lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline as =10 mm in the longest diameter (except lymph nodes which must have a short axis of =15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI), and which is suitable for accurate repeated measurements. - WHO Performance Status 0-2, with no clinically significant deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks; - Adequate bone marrow, renal, hepatic and liver function within 21 days from randomization and defined as follows: - Absolute neutrophil count =1.5 x 109/L; - Platelet count =100 x 109/L; - Haemoglobin =9 g/dL; - Alanine aminotransferase (ALT) =2.5x the upper limit of normal (ULN) if no demonstrable liver metastases or =5xULN in the presence of liver metastases; - Aspartate aminotransferase (AST) =2.5xULN if no demonstrable liver metastases or =5xULN in the presence of liver metastases; - Total bilirubin =1.5xULN if no liver metastases or =3xULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases; - Serum creatinine =1.5xULN concurrent with creatinine clearance =50 mL/min (measured or calculated by Cockcroft and Gault equation); - No significant comorbidity that according to the investigator would hamper the participation on the trial; - Female patients should be using adequate contraceptive measures, should not be breastfeeding, until 12 months after the last dose, and must have a negative pregnancy test (serum or urine) prior to first dose of study drug (within 72 hours); or female patients must have an evidence of non-child-bearing potential by fulfilling one of the following criteria at screening: - Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments. - Women under 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the institution. - Documentation of irreversible surgical sterilisation by hysterectomy, bilateraloophorectomy, or bilateral salpingectomy but not tubal ligation. - Male patients should be willing to use barrier contraception, i.e., condoms o Male patients will be advised to arrange for the freezing of sperm samples prior to the start of the study should they wish to father children, and not to donate sperm until 6 months after discontinuation of study treatment." (as per Investigator Brochure, IB) - Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. Exclusion: - Treatment with any of the following: - Prior treatment with any systemic anti-cancer therapy for locally advanced/metastatic NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug; - Prior treatment with an EGFR-TKI; - Major surgery (excluding placement of vascular access) within 4 weeks before randomization; - Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks before randomization - Patients currently receiving (or unable to stop use at least 1 week prior to receiving the first dose of study drug) medications or herbal supplements known to be potent inhibitors or inducers of cytochrome P450 (CYP) 3A4; - Other anti-cancer therapies and alternative medications such as homeopathic treatment, etc; - Treatment with an investigational drug within five half-lives of the compound or any of its related material, if known; - Leptomeningeal carcinomatosis; spinal cord compression; - Any unresolved toxicities from prior systemic therapy (e.g., adjuvant chemotherapy) greater than CTCAE grade 2 at the time of randomization; - Patients will not be eligible if they have evidence of active malignancy (other than non-melanoma skin cancer or localized cervical cancer or localised and presumed cured prostatic cancer) within 2 years before randomization and are not receiving specific treatment for these malignancies at baseline assessment; - Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol; or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Active infection will include any patients receiving intravenous treatment for infection; active hepatitis B infection will, at a minimum, include all patients who are Hepatitis B surface antigen positive (HbsAg positive) based on serology assessment. Screening for chronic conditions is not required; - Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of Osimertinib or Gefitinib; - Any of the following cardiac criteria: - Mean resting corrected QT interval (QTc) >470 msec, obtained from 3 ECGs using local clinic ECG machine-derived QTcF value - Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG, e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval >250 msec or history of episodes of bradycardia (<50 BPM); - Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval. - Abnormal cardiac function: LVEF < 50% (assessed by MUGA or ECHO) - Past medical history of ILD (Interstitial Lung Disease), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Osimertinib
Osimertinib 60 or 40 mg daily until progression
Gefitinib
Gefitinib 250mg daily until progression

Locations

Country Name City State
France Institut Bergonie Bordeaux
France CHU de Brest Brest
France Centre Francois Baclesse Caen
France Centre Hopitalier Intercommunal De Creteil Créteil
France Assistance Publique - Hopitaux de Marseille - Hopital Nord Marseille
France Institut Paoli-Calmettes Marseille
France Centre Paul Strauss Strasbourg
France CHU Toulouse - Hopital Larrey Toulouse
France Institut de Cancerologie de Lorraine Vandœuvre-lès-Nancy
France Gustave Roussy Villejuif
Jordan King Hussein Cancer Center Amman
Poland Medical University of Gdansk Gdansk
Slovenia University Clinic Golnik Golnik
Slovenia The Institute Of Oncology Ljubljana
Spain Hospital Clinic Universitari de Barcelona Barcelona
Spain Hospital De La Santa Creu I Sant Pau Barcelona
Spain Vall d'Hebron Institut d'Oncologia Barcelona
Spain University Hospital A Coruna-Hospital Teresa Herrera Coruna
Spain Hospital Universitario 12 De Octubre Madrid
Spain Hospital Universitario Ramon y Cajal Madrid
Spain Institut Catala d'Oncologia - ICO Badalona - Hospital De Mataro Mataró
Spain Virgen del Rocio University Hospital Sevilla

Sponsors (2)

Lead Sponsor Collaborator
European Organisation for Research and Treatment of Cancer - EORTC AstraZeneca

Countries where clinical trial is conducted

France,  Jordan,  Poland,  Slovenia,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary PFS Rate at 18 months 24 months after first patient in
Secondary PFS measured from switching to Osimertinib by RECIST criteria 1.1 24 months after first patient in
Secondary Proportion of patients receiving Osimertinib based on the determination of cfDNA T790M mutation positive 24 months after first patient in
Secondary Time to progression on Osimertinib through study completion
Secondary Time to symptomatic brain metastases in patients with presence of brain metastases at study entry 24 months after first patient in
Secondary Overall Response Rate (ORR) to Osimertinib 24 months after first patient in
Secondary Treatment duration 24 months after first patient in
Secondary Overall Survival (OS) 24 months after first patient in
Secondary Time to brain progression (TTBP) 24 months after first patient in
Secondary Safety Number of participants with treatment-related adverse events by CTCAE version 4.0. Adverse events, serious adverse events and adverse reactions will be monitored. 24 months after first patient in
See also
  Status Clinical Trial Phase
Recruiting NCT05821933 - RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC Phase 1/Phase 2
Active, not recruiting NCT03269162 - Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection Phase 3
Recruiting NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Phase 1/Phase 2
Recruiting NCT06315686 - The Dynamic Monitoring of Cerebrospinal Fluid ctDNA Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Recruiting NCT05466149 - Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT03609918 - Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
Recruiting NCT06043817 - First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Phase 1/Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT05078931 - A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients Phase 2
Not yet recruiting NCT05547737 - Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Withdrawn NCT05959473 - EGFR_IUO 3.20 Clinical Study Protocol N/A
Not yet recruiting NCT05005468 - A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. Phase 2
Recruiting NCT01690390 - Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease Phase 2
Completed NCT01852578 - Cabazitaxel in Relapsed and Metastatic NSCLC Phase 2
Active, not recruiting NCT01460472 - Immunotherapy With Racotumomab in Advanced Lung Cancer Phase 3
Completed NCT00702975 - Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy Phase 2
Completed NCT00866970 - Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia Phase 2